USFDA approval granted for Midostaurin Capsules

This USFDA approval paves the way for increased access to this critical treatment for patients, potentially leading to significant cost savings for healthcare systems

68
USFDA Drug product Approval
USFDA Approval

Last Updated on May 26, 2024 by The Health Master

USFDA approval

In a major win for patients and healthcare providers, Lupin Limited (Lupin), a leading global pharmaceutical company, announced today that it has received U.S. Food and Drug Administration approval (USFDA approval) for its generic version of Rydapt® capsules (midostaurin) 25 mg.

This approval allows Lupin to market a more affordable treatment option for patients battling aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).

Treatment Options for Rare Blood Cancers

What are ASM, SM-AHN, and MCL?

These are rare and aggressive types of blood cancers that arise from mast cells, a type of white blood cell involved in the immune system’s response to allergies.

How does midostaurin work?

Midostaurin is a targeted therapy that works by blocking specific signaling pathways that promote the growth and survival of abnormal mast cells.

A More Affordable Treatment Option

  • Rydapt, the brand name drug for midostaurin, had estimated annual sales of USD 75 million in the U.S. (IQVIA MAT March 2024).
  • Lupin’s generic USFDA approval paves the way for increased access to this critical treatment for patients, potentially leading to significant cost savings for healthcare systems.

About Lupin

Lupin Limited is a patient-centric, innovation-driven transnational pharmaceutical company headquartered in Mumbai, India.

They develop and commercialize a wide range of branded and generic formulations, biotechnology products, and APIs (Active Pharmaceutical Ingredients) across various therapeutic areas.

Lupin’s reach extends to over 100 markets globally, including the U.S., India, South Africa, Asia Pacific (APAC), Latin America (LATAM), Europe, and the Middle East.

Lupin’s Commitment to Patient Access

This USFDA approval for generic midostaurin capsules demonstrates Lupin’s ongoing commitment to developing and delivering high-quality, affordable medications for patients worldwide.

The company’s focus on rare diseases like ASM, SM-AHN, and MCL aligns with their mission to improve healthcare access and outcomes for patients with unmet medical needs.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news